Monte Rosa Therapeutics (GLUE) Expected to Post Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2396) per share and revenue of $33.87 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. The business had revenue of $8.97 million during the quarter, compared to the consensus estimate of $12.91 million. On average, analysts expect Monte Rosa Therapeutics to post ($1.23) EPS for the current fiscal year and ($1.56) EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Performance

GLUE stock opened at $10.85 on Thursday. Monte Rosa Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $25.77. The stock’s 50 day simple moving average is $12.25 and its 200 day simple moving average is $17.56. The company has a market cap of $925.65 million, a P/E ratio of -6.16 and a beta of 1.37.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GLUE. HC Wainwright initiated coverage on shares of Monte Rosa Therapeutics in a research report on Thursday, October 1st. They set a “buy” rating and a $25.00 target price for the company. Wells Fargo & Company reduced their price target on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. JPMorgan Chase & Co. cut their price objective on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a report on Friday, August 7th. UBS Group started coverage on shares of Monte Rosa Therapeutics in a research report on Sunday, October 11th. They set a “buy” rating and a $19.00 target price for the company. Finally, Raymond James Financial set a $25.00 target price on shares of Monte Rosa Therapeutics in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.67.

View Our Latest Report on Monte Rosa Therapeutics

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell’s natural protein-degradation machinery. The company’s approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.

Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.

Read More

Earnings History for Monte Rosa Therapeutics (NASDAQ:GLUE)

Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.